FDA, AMA, Others Back New Healthcare Notification Network


By Neil Versel 

March 25, 2008 | A coalition of medical societies, malpractice insurers, pharmaceutical and medical device manufacturers, health plans, and government agencies is trying to end the era of paper patient-safety alerts with the launch of an electronic network to disseminate wide-scale drug and device recalls and warnings.

“We’re talking about moving patient safety online and out of the U.S. Mail,” says Nancy Dickey, M.D., chair of the iHealth Alliance and past president of the American Medical Association. The iHealth Alliance is the governing body of the Medem network, a physician connectivity service founded by national medical societies that is providing the technology to the new Health Care Notification Network (HCNN).

The Health Care Notification Network, publicly unveiled Tuesday morning, is intended to speed up—and ultimately replace—the long-standing process of mailing drug and device warnings and recalls to healthcare providers. “This way, doctors … won’t be hearing of problems first from the media or patients who come into their office, so they won’t be blindsided,” according to Janet Woodcock, M.D., chief medical officer and director of the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA).

The FDA has indicated a preference for e-mail and other electronic forms of communication for disseminating information to the public. The agency has agreed to participate in the HCNN.

Dickey, who also is president of the Texas A&M Health Science Center (College Station, Texas), calls the network a “single, simple organized source for all product-related safety information.”

In addition to speeding up the notification process, the site adds “interactive bells and whistles” to help deliver “more robust information” to clinicians and their patients, according to Medem chief executive Edward Fotsch, M.D.

A typical HCNN screen contains the actual alert in the center column, formatted with the same fonts and colors the FDA recommends for mailed notifications. The left-hand column has links for more information on the drug or device in questions—including images—as well as a link for the user to contact the manufacturer. The right side of the screen has suggestions on how care providers can notify patients, plus a link to the FDA MedWatch reporting program.

Doctors who have Web portals through Medem can send the alerts to their sites and e-mail the information directly to patients with iHealthRecords, Medem’s personal health record (PHR) product, Fotsch says.

Alerts will be tailored to specialties so physicians are not overwhelmed with every notice for every device or drug. “Nothing will make people discard information faster than receiving a large number of irrelevant alerts,” Dickey says.

There is no charge for healthcare providers to participate. “If you can get patient safety today on a free network, you’re hard-pressed to wait two weeks [for a manufacturer to print and mail a paper alert],” Fotsch says.

Malpractice insurance carriers, through the Physician Insurance Association of America (PIAA), are supporting HCNN as an essential element of patient safety, and the Joint Commission has endorsed the effort. “I am asking our insured physicians to enroll in the HCNN and receive their FDA-related patient safety notifications online,” says David Troxel, M.D., medical director of malpractice insurer The Doctors Co.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.